These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 20881216)

  • 1. Evaluation and recommendations on adaptive dose-ranging trials: highlights from the PhRMA Adaptive Dose-Ranging Studies Working Group.
    Pinheiro J
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):47S-49S. PubMed ID: 20881216
    [No Abstract]   [Full Text] [Related]  

  • 2. Innovative approaches for designing and analyzing adaptive dose-ranging trials.
    Bornkamp B; Bretz F; Dmitrienko A; Enas G; Gaydos B; Hsu CH; König F; Krams M; Liu Q; Neuenschwander B; Parke T; Pinheiro J; Roy A; Sax R; Shen F
    J Biopharm Stat; 2007; 17(6):965-95. PubMed ID: 18027208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discussion of "The White Paper of the PhRMA Working Group on adaptive dose-ranging designs".
    Hemmings R
    J Biopharm Stat; 2007; 17(6):1021-7; discussion 1029-32. PubMed ID: 18027213
    [No Abstract]   [Full Text] [Related]  

  • 4. Discussion of the "White Paper of the PhRMA Working Group on adaptive dose-ranging designs".
    Grieve AP
    J Biopharm Stat; 2007; 17(6):997-1004; discussion 1029-32. PubMed ID: 18027209
    [No Abstract]   [Full Text] [Related]  

  • 5. Discussion of the "White Paper of the PhRMA PISC Working Group on adaptive dose-ranging designs".
    Leonov S
    J Biopharm Stat; 2007; 17(6):1013-4; discussion 1029-32. PubMed ID: 18027211
    [No Abstract]   [Full Text] [Related]  

  • 6. Adaptive designs in clinical drug development--an Executive Summary of the PhRMA Working Group.
    Gallo P; Chuang-Stein C; Dragalin V; Gaydos B; Krams M; Pinheiro J;
    J Biopharm Stat; 2006 May; 16(3):275-83; discussion 285-91, 293-8, 311-2. PubMed ID: 16724485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A proof-of-concept clinical trial design combined with dose-ranging exploration.
    Wang X; Ting N
    Pharm Stat; 2012; 11(5):403-9. PubMed ID: 22714951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discussion of the paper "Adaptive dose-ranging designs".
    Burman CF
    J Biopharm Stat; 2007; 17(6):1005-11; discussion 1029-32. PubMed ID: 18027210
    [No Abstract]   [Full Text] [Related]  

  • 9. "Getting the dose right": facts, a blueprint, and encouragements.
    Peck CC; Cross JT
    Clin Pharmacol Ther; 2007 Jul; 82(1):12-4. PubMed ID: 17571068
    [No Abstract]   [Full Text] [Related]  

  • 10. Viewpoints on the FDA draft adaptive designs guidance from the PhRMA working group.
    Gallo P; Anderson K; Chuang-Stein C; Dragalin V; Gaydos B; Krams M; Pinheiro J
    J Biopharm Stat; 2010 Nov; 20(6):1115-24. PubMed ID: 21058107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacometrics 2020.
    Gobburu JV
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):151S-157S. PubMed ID: 20881229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discussion of the "White Paper of the PhRMA Working Group on adaptive dose-ranging designs".
    Wang SJ
    J Biopharm Stat; 2007; 17(6):1015-20; discussion 1029-32. PubMed ID: 18027212
    [No Abstract]   [Full Text] [Related]  

  • 13. Dose-ranging in clinical trials: rationale and proposed use with placebo or positive controls.
    Freston JW
    Am J Gastroenterol; 1986 May; 81(5):307-11. PubMed ID: 3706243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. American College of Clinical Pharmacology position statement on the use of microdosing in the drug development process.
    Bertino JS; Greenberg HE; Reed MD;
    J Clin Pharmacol; 2007 Apr; 47(4):418-22. PubMed ID: 17389550
    [No Abstract]   [Full Text] [Related]  

  • 15. Benefit-risk assessment: to quantify or not to quantify, that is the question.
    Yuan Z; Levitan B; Berlin JA
    Pharmacoepidemiol Drug Saf; 2011 Jun; 20(6):653-6. PubMed ID: 21538675
    [No Abstract]   [Full Text] [Related]  

  • 16. Adaptive designs for Phase I dose-finding studies.
    Zhou Y
    Fundam Clin Pharmacol; 2010 Apr; 24(2):129-38. PubMed ID: 19703268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive modelling of dose-response relationships using smoothing splines.
    Kirby S; Colman P; Morris M
    Pharm Stat; 2009; 8(4):346-55. PubMed ID: 19205006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Choice of designs and doses for early phase trials.
    Zhou Y
    Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approaches to Japanese dose evaluation in global drug development: factors that generate different dosages between Japan and the United States.
    Nakashima K; Narukawa M; Takeuchi M
    Clin Pharmacol Ther; 2011 Dec; 90(6):836-43. PubMed ID: 22048222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose finding - a challenge in statistics.
    Bretz F; Hsu J; Pinheiro J; Liu Y
    Biom J; 2008 Aug; 50(4):480-504. PubMed ID: 18663758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.